Evidence map›Paper›PMID 24909160›Full record

ArticleOncogene2015

Stem cell programs are retained in human leukemic lymphoblasts.

D Fan, X Zhou, Z Li, Z-Q Li, C Duan, T Liu, F Zhang, Y Huang, Y Zhang, F Gao and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

D FanKey Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China.
X ZhouKey Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, SJTU-SM, Shanghai, China.
Z LiRuijin Hospital, SJTU-SM, Shanghai, China.
Z-Q LiKey Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, SJTU-SM, Shanghai, China.
C DuanRuijin Hospital, SJTU-SM, Shanghai, China.
T LiuRuijin Hospital, SJTU-SM, Shanghai, China.
F ZhangKey Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China.
Y HuangKey Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, SJTU-SM, Shanghai, China.
Y ZhangShanghai Cord Blood Bank, Shanghai, China.
F GaoShanghai Cord Blood Bank, Shanghai, China.
Y GuoStem Cell Laboratory, UCL Cancer Institute, University College London, London, UK.
R GuptaStem Cell Laboratory, UCL Cancer Institute, University College London, London, UK.
G ChenKey Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, SJTU-SM, Shanghai, China.
T EnverStem Cell Laboratory, UCL Cancer Institute, University College London, London, UK.
J TangKey Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China.
D Hong1] Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China [2] Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, SJTU-SM, Shanghai, China.

Funding

Cancer Research UK 12796Medical Research Council G1000801GMedical Research Council MC_QA137913Medical Research Council MC_U137973817
6 · The paper itself

Abstract

Leukemic lymphoblasts within different immunophenotypic populations possess stem cell properties. However, whether or not the self-renewal program is retained from stem cells or conferred on progenitors by leukemogenic molecules remains unknown. We have addressed the issue in the context of TEL-AML1-associated acute lymphoblastic leukemia (ALL) by profiling a refined program edited from genes essential for self-renewal of hematopoietic stem cells and B-cell development. Bioinformatic analysis shows that ALL populations are loosely clustered and close to the normal population that contains stem and primitive progenitor cells. This finding indicates that immunophenotypes do not reflect maturation stages in ALL and that the self-renewal program may be retained from stem cells. Results of assessing 'first hit' function of TEL-AML1 in different populations of normal cells demonstrate the molecular model. Therefore, the current study shows a leukemogenic scenario of human ALL in which programs of stem cells are sustained in distinct fractions by leukemogenic mutations.

Indexed as

AdolescentADP-ribosyl Cyclase 1Antigens, CD19Antigens, CD34B-LymphocytesChildChild, PreschoolCore Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinFemaleGene Expression ProfilingHematopoiesisHematopoietic Stem CellsHumansInfantMaleADP-ribosyl Cyclase 1Antigens, CD19Antigens, CD34Core Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinOncogene Proteins, FusionTEL-AML1 fusion protein

Identifiers

PMID24909160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.